Artificial intelligence is rapidly becoming one of the most discussed technologies in healthcare and clinical research.
The possibilities are compelling.
Could AI help identify suitable clinical trial sites?
Could it find potentially eligible patients more efficiently?
Could algorithms detect safety patterns earlier?
Could clinical data be reviewed faster?
Could generative AI assist with medical writing, document review or
operational workflows?
Potentially, yes.
But there is another question that matters just as much:
Can we trust the output?
Clinical research operates in a highly regulated environment where
decisions can affect participant safety, scientific conclusions and ultimately
whether a medicine reaches patients.
That means the future of AI in clinical research cannot simply be about automation.
It must be about responsible, validated and fit-for-purpose
automation supported by appropriate human oversight.
Clinical Research Was Becoming Digital Before Generative AI Arrived
The digital transformation of clinical trials did not begin with ChatGPT
or large language models.
Clinical research has been moving from paper-based processes toward
interconnected digital systems for years.
A modern trial may involve:
EDC — Electronic Data Capture
CTMS — Clinical Trial Management System
eTMF — Electronic Trial Master File
RTSM/IRT — Randomization and Trial Supply
Management
eConsent
eCOA/ePRO
Safety databases
Central laboratory systems
Imaging platforms
Wearable and sensor technologies
Electronic health records
Each system generates, processes or transfers information.
AI represents another layer in this evolution—one capable not only of
storing or transmitting information but of identifying patterns, making
predictions and generating content.
That capability creates enormous opportunity.
It also creates new forms of risk.
Where Could AI Support Clinical Research?
The potential applications span almost the entire clinical development
lifecycle.
1. Protocol Design
AI and advanced analytics may help researchers interrogate historical
trial data, literature, epidemiology and operational information.
Potential applications include identifying:
- Common protocol
amendments
- Complex
eligibility criteria
- Potential
recruitment barriers
- Endpoint patterns
- Historical trial
performance
- Patient burden
This could support more informed protocol development.
But AI should not independently decide what constitutes an ethically or
scientifically appropriate clinical trial.
That requires multidisciplinary expertise.
2. Country and Site Selection
Traditional site selection often relies on investigator networks,
feasibility questionnaires and historical relationships.
Data-driven approaches can potentially incorporate:
- Historical
enrollment
- Disease
prevalence
- Site performance
- Competing trials
- Investigator
experience
- Activation
timelines
- Geographic
patient distribution
AI may help identify patterns across these datasets.
But a model cannot necessarily understand every local operational
reality.
A site predicted to recruit well may have:
- Lost its
experienced CRC
- Opened competing
studies
- Changed referral
pathways
- Limited pharmacy
capacity
- Contracting
delays
Analytics can inform feasibility. They cannot replace local
intelligence.
3. Patient Identification and Recruitment
AI may potentially support identification of patients who appear to meet
trial eligibility criteria using structured and unstructured healthcare data.
This is particularly attractive for studies involving:
- Complex
eligibility criteria
- Rare diseases
- Biomarker-defined
populations
- Large healthcare
datasets
Instead of manually reviewing thousands of records, algorithms may help
identify potential candidates for appropriate clinical review.
But eligibility is not merely a data-matching exercise.
Clinical context matters.
Final eligibility decisions must follow the protocol and remain under
appropriate qualified human responsibility.
Privacy, consent and applicable data-protection requirements must also
be considered.
4. Clinical Data Management
Clinical trials generate increasingly large and complex datasets.
AI-supported tools may potentially assist with:
- Data anomaly
detection
- Missing-data
identification
- Query
prioritization
- Pattern
recognition
- Data
reconciliation
- Coding support
The value may lie less in replacing data managers and more in allowing
them to focus attention where human expertise adds the greatest value.
Instead of manually reviewing every data point with equal intensity,
technology may help prioritize unusual or potentially important patterns.
This aligns with the broader movement toward risk-proportionate clinical
trial quality management.
5. Risk-Based Monitoring
Monitoring is another area where analytics can support more targeted
oversight.
Centralized monitoring systems can evaluate data across sites to
identify patterns such as:
- Unusual
protocol-deviation rates
- Missing data
- Delayed data
entry
- Atypical safety
reporting
- Unusual
enrollment patterns
- Statistical
anomalies
- Outlying site
behaviour
A CRA may then investigate the sites or processes presenting the
greatest potential risk.
This does not eliminate the CRA.
It changes the information available to the CRA.
The future of monitoring is therefore unlikely to be:
Human OR technology.
It is more likely to be:
Human expertise + better technology + risk-based decision-making.
6. Pharmacovigilance
Pharmacovigilance generates large volumes of structured and unstructured
information.
AI and natural language processing may support activities such as:
- Identification of
potential adverse-event information
- Case intake
- Duplicate
detection
- Coding support
- Literature
screening
- Case
prioritization
- Trend
identification
- Signal detection
support
EMA has specifically recognized pharmacovigilance, including
adverse-event report management and signal detection, as an area where AI tools
may support the medicine lifecycle.
However, an algorithm identifying a statistical pattern is not
equivalent to a medical conclusion.
Signal evaluation still requires clinical context, causality assessment
and benefit-risk judgment.
7. Medical Writing
Generative AI has obvious implications for medical and regulatory
writing.
Potential uses include:
- Creating initial
document structures
- Summarizing
source material
- Comparing
document versions
- Identifying
inconsistencies
- Supporting
literature review
- Formatting
information
- Assisting with
plain-language content
These applications may improve efficiency.
But medical writing is not simply text generation.
Regulatory documents must be:
accurate, traceable, internally consistent, scientifically justified and
aligned with source data.
A fluent paragraph can still be factually wrong.
This is particularly important because generative AI systems can produce
information that sounds authoritative even when it is unsupported or incorrect.
Human scientific review therefore remains indispensable.
8. Trial Master File and Document Management
AI may also support document-intensive processes.
Potential applications include:
- Document
classification
- Metadata
extraction
- Filing
recommendations
- Completeness
checks
- Duplicate
identification
- Quality-control
support
- Search and
retrieval
For large global studies, these tools could reduce administrative
burden.
But an AI-enabled eTMF still needs appropriate governance.
The sponsor remains responsible for ensuring that essential records
adequately demonstrate how the trial was conducted.
Automation cannot become an excuse for poor documentation.
9. Predictive Analytics
Could AI predict which sites will underperform?
Which participants may discontinue?
Which operational risks may become critical?
Possibly.
Predictive analytics can identify relationships across large historical
datasets that may not be obvious through manual review.
But prediction is not certainty.
A model can be:
- Incorrect
- Poorly calibrated
- Biased
- Trained on an
unrepresentative population
- Applied outside
its intended context
- Degraded as
circumstances change
This is why model performance must be understood in relation to its context
of use.
The Most Important Question: What Is the Context of Use?
One of the strongest themes emerging from regulatory thinking around AI
is that an AI model cannot simply be labelled “validated” in the abstract.
Its credibility depends on what it is being used to do.
Consider the difference between an AI system used to:
A. Format internal meeting notes
and
B. Generate information contributing directly to a regulatory conclusion
about treatment safety or effectiveness.
The consequences of failure are very different.
The degree of evidence and control needed should therefore also differ.
FDA's current draft framework for AI used to support regulatory
decision-making is explicitly risk-based and context-of-use driven.
The principle is important well beyond regulatory submissions:
The greater the consequence of an incorrect AI output, the stronger the
evidence and oversight required to trust it.
A Major 2026 Development: FDA and EMA Align on Good AI Practice
In January 2026, FDA and EMA jointly published 10 Guiding Principles
of Good AI Practice in Drug Development.
The principles cover:
- Human-centric
design
- Risk-based
approaches
- Adherence to
standards
- Clear context of
use
- Multidisciplinary
expertise
- Data governance
and documentation
- Model design and
development practices
- Risk-based
performance assessment
- Lifecycle
management
- Clear and
essential information
This is an important development.
It signals that regulators are not approaching AI simply as a software
question.
AI governance in medicine development involves:
people + data + algorithms + scientific purpose + risk + lifecycle
management.
AI Is Only as Reliable as the Data Behind It
The phrase “garbage in, garbage out” remains relevant.
Imagine training a site-selection model primarily using data from large
academic hospitals in North America.
Can we assume that its predictions will work equally well for:
- Community
hospitals?
- European sites?
- Japanese
hospitals?
- Emerging research
markets?
- Rare-disease
networks?
Not necessarily.
AI models can inherit limitations from their training data.
Potential data problems include:
- Missingness
- Measurement error
- Inconsistent
definitions
- Historical bias
- Underrepresentation
- Data drift
- Incorrect labels
More data do not automatically solve these problems.
Data quality and representativeness matter.
Bias Is Not Merely a Technical Problem
Suppose an AI system is used to identify patients potentially eligible
for a trial.
If the underlying healthcare dataset systematically underrepresents a
particular population, the algorithm may also identify fewer candidates from
that population.
The system may be functioning exactly as programmed—and still produce
inequitable results.
This is why responsible AI requires examination of:
- Dataset
representativeness
- Subgroup
performance
- Potential sources
of bias
- Clinical
consequences of errors
AI governance therefore needs input from more than data scientists.
Clinicians, statisticians, clinical operations professionals, quality
experts, regulatory specialists and patient perspectives may all be relevant.
Explainability and Transparency Matter
Not every advanced model is easily interpretable.
In some situations, a highly complex model may produce accurate
predictions without providing a simple explanation for how it reached them.
Whether that is acceptable depends on the context.
For a low-risk administrative task, limited explainability may be
tolerable.
For a model influencing an important clinical or regulatory decision,
greater understanding may be required.
The question is not simply:
“Does the model work?”
It may also be:
“Do we understand its limitations sufficiently to use it responsibly?”
Validation Cannot Be a One-Time Event
Traditional software validation can sometimes create the impression:
Validate → Deploy → Done
AI models complicate this.
Performance may change over time because:
- Patient
populations change
- Clinical practice
changes
- Data sources
change
- Input
distributions shift
- Software is
updated
- Models are
retrained
This is often described as model drift or data drift.
Responsible AI therefore requires lifecycle management.
A model that performed well two years ago cannot automatically be
assumed to perform identically today.
This aligns directly with the 2026 FDA-EMA principles emphasizing
lifecycle management and risk-based performance assessment.
Data Integrity Still Applies in the AI Era
AI does not remove traditional clinical research requirements.
If AI interacts with trial data, teams still need to consider:
- Data provenance
- Audit trails
- Access controls
- Validation
- Security
- Change control
- Backup and
recovery
- Traceability
- Record retention
ICH E6(R3) explicitly recognizes modern computerized systems and data
sources and applies a risk-based approach to validation based on intended use
and potential impact on participant protection and reliability of trial
results.
That principle applies whether a system is described as:
digital, automated, intelligent, AI-enabled—or simply software.
What About Generative AI and Confidential Trial Information?
This is one of the most immediate practical questions for clinical
research organizations.
Employees can now access powerful generative AI tools within seconds.
But copying confidential trial information into an uncontrolled public
AI environment may create significant concerns involving:
- Confidentiality
- Personal data
- Intellectual
property
- Sponsor
information
- Data residency
- Information
security
- Contractual
obligations
Organizations therefore need clear policies defining:
Which AI systems are approved?
What information may be entered?
What information is prohibited?
How are outputs reviewed?
How are activities documented where necessary?
Who remains accountable for the final work product?
AI adoption without governance can create risk faster than it creates
efficiency.
Human-in-the-Loop Is More Than a Catchphrase
“Human oversight” is frequently mentioned in discussions about
responsible AI.
But meaningful human oversight requires more than clicking Approve.
The reviewer needs:
- Appropriate
expertise
- Access to the
underlying evidence
- Sufficient time
- Authority to
reject the output
- Understanding of
the system's limitations
If humans automatically accept AI-generated outputs because the
technology is perceived as more intelligent, human oversight becomes
ceremonial.
The goal is not simply to keep a person somewhere in the workflow.
It is to maintain meaningful human accountability.
What AI Should Not Become
Clinical research should avoid using AI simply because it is
fashionable.
A useful technology should solve a defined problem.
Before implementing an AI solution, organizations should ask:
What problem are we solving?
Is AI actually necessary?
What is the intended context of use?
What happens if the model is wrong?
What data does it require?
How will performance be evaluated?
How will humans oversee it?
How will changes be controlled?
How will we know when it stops performing adequately?
Sometimes the best solution may be AI.
Sometimes it may be conventional automation.
Sometimes it may simply be a better-designed process.
Digital transformation should begin with the problem—not the technology.
Will AI Replace Clinical Research Professionals?
AI will almost certainly change clinical research roles.
But “replacement” oversimplifies what these roles involve.
Consider a CRA.
Monitoring involves more than checking data.
A strong CRA understands:
- Site behaviour
- Investigator
engagement
- Protocol
implementation
- Participant
safety
- Documentation
- Operational risk
- Communication
- Escalation
Or consider a medical writer.
Writing involves more than producing grammatically correct sentences.
It requires:
- Scientific
interpretation
- Source evaluation
- Regulatory
understanding
- Consistency
- Judgment
- Accountability
Or consider a pharmacovigilance physician.
Signal evaluation requires more than identifying correlations.
It requires clinical reasoning and benefit-risk assessment.
AI may automate parts of these workflows.
That could make human expertise more—not less—important, because
professionals may increasingly spend their time interpreting, validating and
acting on information generated by technology.
The Real Opportunity: Augmented Clinical Research
Perhaps the most productive way to think about AI is not artificial
intelligence replacing human intelligence.
It is:
Technology augmenting human expertise.
Imagine:
AI identifies the anomaly → the data manager investigates it.
Analytics identify a high-risk site → the CRA determines why.
AI detects a possible safety pattern → the safety physician evaluates
its clinical significance.
AI drafts an initial document → the medical writer verifies every
scientific conclusion.
AI identifies potential participants → qualified site staff confirm
eligibility.
That model combines computational scale with human judgment.
And that may be where AI provides its greatest value.
The Agile Clinical Trendz Perspective
At Agile Clinical Trendz, we believe digital transformation
should improve clinical research without weakening the principles that make
clinical evidence trustworthy.
AI can potentially support:
efficiency, scalability, pattern recognition, risk identification and
better use of complex data.
But responsible adoption requires equal attention to:
validation, data governance, privacy, security, bias, traceability,
regulatory expectations and human oversight.
The question clinical research organizations should ask is therefore
not:
“How much AI are we using?”
It is:
“Where can technology genuinely improve clinical research—and what
controls are necessary to ensure that improvement remains trustworthy?”
The organizations that succeed in the AI era will not necessarily be
those that automate the most.
They will be those that understand what to automate, what to
validate, what to monitor—and what must remain a matter of qualified human
judgment.
Because innovation and quality are not competing priorities.
Responsible innovation requires both.
References
- U.S. Food and
Drug Administration. Guiding Principles of Good AI Practice in Drug
Development. January 2026.
- European
Medicines Agency; U.S. Food and Drug Administration. Guiding Principles
of Good AI Practice in Drug Development. 2026.
- U.S. Food and
Drug Administration. Considerations for the Use of Artificial
Intelligence to Support Regulatory Decision-Making for Drug and Biological
Products. Draft Guidance for Industry and Other Interested Parties.
January 2025.
- European
Medicines Agency. Reflection Paper on the Use of Artificial
Intelligence in the Medicinal Product Lifecycle. Adopted September
2024.
- International
Council for Harmonisation. ICH E6(R3): Guideline for Good Clinical
Practice. Final Guideline. 2025.